LION
LIVE

Serial Number

97575104

Owner

HDT Bio Corp.

Attorney

Draeke H. Weseman

Filing Date

Sep 1, 2022

Add to watchlist:

No watchlists yet
View on USPTO

LION Trademark

Serial Number: 97575104

LION is a trademark filed by HDT Bio Corp. on September 1, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

HDT Bio Corp. (3 trademarks)

1616 Eastlake Ave. E, Suite 280
Seattle, WA 98501

Entity Type: 03

Trademark Details

Filing Date

September 1, 2022

Registration Date

Not Registered

Published for Opposition

January 14, 2025

Goods & Services

Nanoparticle formulations as components of nucleic acid-based vaccines, medicines, and pharmaceutical preparations, namely, nucleic acid drug delivery agents comprising cationic nanoparticle compositions that complex with one or more nucleic acids for the purpose of delivering such nucleic acid to biological cells for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoemulsion compositions as components of nucleic acid-based vaccines, medicines, and pharmaceutical preparations, namely, nucleic acid drug delivery agents in the nature of compounds combining liquid oils, lipids, and surfactants to form nanoparticles to facilitate the delivery of nucleic acids to biological cells, for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Therapeutic preparations in the nature of vaccines as drug delivery agents consisting of nucleic acid, protein or small-molecule compounds for medicines that facilitate the delivery of a wide range of pharmaceuticals delivered via intramuscular injections, intravenous injections, inhalation, transdermal, intradermal, or intranasal methods, for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations as components of immunotherapeutics, namely, pharmaceutical preparations in the nature of vaccines and nucleic acid, protein or small-molecule medicines for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations in the nature of active pharmaceutical ingredient drug delivery agents consisting of compositions in the nature of cationic nanoparticles that facilitate the delivery of medical, biological, pharmaceutical, and therapeutic preparations to biological cells for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations in the nature of compositions for use as drug delivery agents sold as an integral component of pharmaceutical preparations; Nanoparticles and nanoparticle formulations in the nature of active pharmaceutical ingredients for use as drug delivery agents consisting of a biological composition in the form of nanoparticles sold as an integral component of pharmaceutical preparations for intracellular delivery of nucleic acid to biological cells for the treatment and prevention of a wide variety of diseases, namely, cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases, all for pharmaceutical or medical purposes; Pharmaceutical preparations, namely, lipid-enabled drug delivery systems for nucleic acid, protein or small-molecule medicines comprising small interfering RNA, messenger RNA, antisense, microRNA, DNA, cDNA oligotherapeutic, protein therapeutic agents, and small molecules that facilitate the delivery of pharmaceutical preparations to biological cells to enable the targeting of any gene in the human genome to modulate immune response, sold to pharmaceutical companies for use as an integral component for use in the further manufacture of pharmaceutical preparations for the treatment and prevention of a wide variety of diseases, namely, cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Pharmaceutical preparations for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Pharmaceutical preparations, namely, nucleic acid-based delivery agents comprised of nanoparticle carriers and polymers for the delivery of nucleic acid to human cells; Drug carriers for medical use, namely, drug delivery agents consisting of cationic nanoparticles as compositions that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents consisting of emulsions as compositions that facilitate delivery of a wide range of pharmaceuticals

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 5, 2026 EXRA
SOU EXTENSION 2 GRANTED
Mar 5, 2026 EX2G
SOU EXTENSION 2 FILED
Mar 4, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 4, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 13, 2025 EXRA
SOU EXTENSION 1 GRANTED
Nov 12, 2025 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 12, 2025 AITU
SOU EXTENSION 1 FILED
Sep 10, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 10, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 14, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 14, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 8, 2025 NONP
EXPARTE APPEAL TERMINATED
Dec 20, 2024 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 20, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 20, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 20, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 20, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 20, 2024 CNEA
DIVISIONAL PROCESSING COMPLETE
Nov 14, 2024 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 12, 2024 AITU
ASSIGNED TO LIE
Nov 12, 2024 ALIE
DIVISIONAL REQUEST RECEIVED
Aug 28, 2024 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Aug 28, 2024 ERTD
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 28, 2024 ERFR
EX PARTE APPEAL-INSTITUTED
Aug 28, 2024 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Aug 28, 2024 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Aug 28, 2024 EXAF
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 26, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 26, 2024 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 28, 2024 GNFN
FINAL REFUSAL E-MAILED
Feb 28, 2024 GNFR
FINAL REFUSAL WRITTEN
Feb 28, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 15, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 13, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 12, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 12, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 13, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jul 13, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jul 13, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 17, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 9, 2022 NWOS
NEW APPLICATION ENTERED
Sep 5, 2022 NWAP